UPDATE: Mizuho Securities USA Initiates Coverage on NewLink Genetics Corp. with Buy Rating, $50 PT on Emerging Market Pure Play

In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on

with a Buy rating and $50.00 price target. In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of NewLink Genetics with a Buy rating and a price target of $50. NewLink is a pure play on the rapidly emerging immuno-oncology market, with substantial near-term catalysts that start 1Q15, a pipeline of 7 therapeutics across multiple settings using both small molecule and biological drugs and two late Phase III trials.” NewLink Genetics Corp. closed on Thursday at $26.68.